Amneal Pharmaceuticals, Inc. 8-K

What Happened
Amneal Pharmaceuticals, Inc. filed an 8-K on January 13, 2026 in connection with a presentation at an investor conference, announcing it expects to meet or exceed its previously stated 2025 full-year financial guidance (originally disclosed Oct. 30, 2025). The company also estimated its net leverage as of December 31, 2025 to be approximately 3.6x, down from 3.9x at December 31, 2024.

Key Details

• 2025 guidance ranges: Net revenue $3.0B–$3.1B; Adjusted EBITDA $675M–$685M; Adjusted diluted EPS $0.75–$0.80.
• Cash flow and capex: Operating cash flow $300M–$330M; Capital expenditures approximately $100M (net of ~$20M expected alliance contribution).
• Net leverage: Estimated ~3.6x at 12/31/2025 vs 3.9x at 12/31/2024 (see prior 8-K filed 2/28/2025 for the 2024 calculation).
• Non-GAAP notes: Adjusted measures include 100% of AvKARE adjusted EBITDA and reflect a 35% non-controlling interest in AvKARE for adjusted EPS; company said it cannot reconcile these non-GAAP guidance figures to GAAP without unreasonable effort due to unavailable year-end items.

Why It Matters
For investors, the filing signals management expects full-year performance to meet or exceed prior targets and indicates modest deleveraging year-over-year. The guidance provides concrete revenue, EBITDA, EPS, cash flow and capex ranges to evaluate near-term performance, but investors should note these are non-GAAP forward estimates and the company warned reconciliation to GAAP isn’t available now and results remain subject to final close and potential adjustments. The filing is a forward-looking operational update — not final audited results.